RxDoctor Payments Data

Stanley Ireland, MD

Family Medicine · Flintstone, GANPI 1023095536

Payments from drug & device makers

$9,009in general payments, 2019–2025

Across 533 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$900
  • Amgen$676
  • GSK$625
  • Sanofi-aventis U.S. LLC$549
  • Astellas Pharma US Inc$548
  • plus $5K from 40 others

What the payments were for

  • Food & beverage$8,78598%
  • Education$2242%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,009 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$24,788
Medicare patients
87
Services billed
624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban180$143,626
Tresiba Flextouch U-200Insulin Degludec136$129,629
GlyxambiEmpagliflozin/Linagliptin74$68,556
MounjaroTirzepatide63$66,496
OzempicSemaglutide39$49,352
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$40,205
JardianceEmpagliflozin49$39,108
XareltoRivaroxaban43$38,034
FarxigaDapagliflozin Propanediol47$36,260
EntrestoSacubitril/Valsartan22$28,945
Repatha SureclickEvolocumab39$22,207
LinzessLinaclotide17$15,165
ArexvyRsvpref3 Antigen/As01e/Pf42$13,348
MyrbetriqMirabegron19$13,332
Trijardy XrEmpaglifloz/Linaglip/Metformin13$9,147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$498$143,626180 claims
Boehringer IngelheimGlyxambi, Jardiance, Trijardy Xr$312$116,811136 claims
Lilly USA, LLCMounjaro$272$66,49663 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$625$59,557127 claims
Novo NordiskOzempic, Novolog$900$51,46651 claims
Johnson & JohnsonXarelto$98$38,03443 claims
AstraZenecaFarxiga$134$36,26047 claims
NovartisEntresto$127$28,94522 claims
AbbVieLinzess$1,152$15,16517 claims
Astellas Pharma US IncMyrbetriq$548$13,33219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Flintstone

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →